Genentech buys Regor’s CDK inhibitors in $850m deal
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including oncology.
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including oncology.
What's Your Reaction?
